‡ In these countries please contact our distributor

Acticoat* Retrospective

Smith & Nephew logo


Acticoat Antimicrobial Barrier Dressing logo


Acticoat* (with SILCRYST TM Nanocrystals) and Health Economics

Acticoat Retrospective/Prospective Cost Analysis

To better understand the cost-effectiveness of Acticoat at an individual patient level, a retrospective/prospective treatment cost analysis was conducted on many of the case studies represented in this booklet. This analysis compares the cost of treatment of a patient's wound to date using conventional therapy (without achieving healing) with the cost of healing a wound using Acticoat as an adjunct therapy.


The objective of this cost analysis is to put the purchase price of Acticoat into perspective with the cost of conventional treatment the patient has received to date in the management of their wound. One of the assumptions underpinning the cost analysis is that the pattern and cost of wound care over the period leading up to the current point in time is likely to be duplicated for a similar period after this point if the wound care treatment remains unchanged. i.e. if you continue with the same treatment regime it is reasonable to expect the same health outcomes.


The implication of this cost analysis for the healthcare system is that early intervention with Acticoat on patients who are unresponsive to conventional wound care management is likely to avoid indefinitely ongoing consumption of healthcare resources, at the levels identified in Table 1.


Good data are available which show the average weekly cost of conventional treatment of various wound types. (UK treatment patterns and costs (2000))


Table 1. Weekly Treatment Costs

Clinical Indication: Average cost to treat per week:
Diabetic foot ulcers    
  • Ambulatory setting
£230 €353
Venous leg ulcers    
  • Usual care (non compression)
£44 €68
  • Profore
£27 €41
Pressure ulcers    
  • Grade 1
£270 €414
  • Grade 2
£380 €583
  • Grade 3
£546 €838
  • Grade 4
£678 €1,040

Figures compiled in 2003


Retrospective Costs

The patient information used for retrospect costs was 'weeks of treatment'.

The retrospective treatment cost to date was calculated using the weeks of treatment for a patient multiplied by the average weekly cost to treat the applicable clinical indication (see Table 1).


It is important to recognise that this cost represents the cost of treating a patient without achieving a healed wound.


Prospective Costs

The patient information used for prospective costs was 'weeks of treatment with Acticoat and 'time to heal'.


The prospective treatment cost was calculated using the number of pieces of Acticoat used multiplied by the purchase price (see Table 2). Only the product cost of Acticoat is considered as the additional cost to heal the ulcer as the cost of ongoing clinic visits and conventional wound management products would have been incurred irrespective of treatment choice. ( Acticoat is an adjunct therapy, used in combination with conventional wound management products)


It is important to note that this cost represents the cost to heal a patient's wound, with the use of Acticoat.


Table 2. Acticoat Price

  Representative unit purchase price:
Representative Acticoat product: £
Acticoat 7 (10cm x 12.5cm) £11.20 €17.18

Figures compiled in 2003


Nanocrystalline Silver is a patented technology of NUCRYST Pharmaceuticals Corp.
TM SILCRYST is a trademark of NUCRYST Pharmaceuticals Corp, used under licence